Immunogenicity and adverse effects of the third booster dose with ChAdOx1 among dental care workers after receiving a full dose of CoronaVac

Main Article Content

Poompat Leechanavanichpan
Pitchaya Tunlayadechanont
Nantana Sriudomporn
Chavachol Setthaudom
Rapeephan R Maude
Sittichoke Osiri

Abstract

Dental care workers have very high risks of SARS-CoV-2 infection since most of the dental operations require aerosol-generating procedures which could potentially spread the virus in treatment areas. As a result, vaccination can be an important tool in protecting dental care workers from infection.


Objective: To investigate the adverse effects and immunogenicity after receiving third dose of viral vector (ChAdOx1) vaccine among dental care workers who fully vaccinated with inactivated (CoronaVac) vaccine.


Materials and Methods: Blood samples from 57 subjects were collected three times. Sixty days after fully vaccinated with CoronaVac (baseline), 14-21 days and 90-104 days after receiving ChAdOx1 booster dose. Blood samples were tested for immunity against SARS-CoV-2, including Anti-SARS-CoV-2 spike receptor-binding domain (RBD) IgG, Neutralizing antibody (sVNT) and Anti-nucleocapsid (N) protein IgG. Adverse effects were reported using questionnaire.


Results: At baseline, all subjects had an anti-RBD IgG titer greater than the cut-off value, while 43.8% had sVNT lower than the cut-off value. The anti-RBD IgG titer and sVNT appeared to increase in the second serum test yet reduced in the last test. At baseline, 40% of participants had anti-N IgG levels that were higher than the cut-off value. Anti-N IgG levels, along with the number of participants with values above the cut-off, have been declining in the other two serum tests. The majority of the participants experienced mild to moderate symptoms. Most of the symptoms subsided after a few days.


Conclusion: Receiving booster dose of ChAdOx1 after CoronaVac full vaccination can stimulate strong immune response against SARS-CoV-2 with no serious adverse effects. Although level of immunity declines within 3 months, neutralizing activity is still high. However, the protective efficacy tended to reduce overtime. To minimize the risk of infection, healthcare workers should follow prevention guidelines both inside and outside working hours.

Article Details

How to Cite
1.
Leechanavanichpan P, Tunlayadechanont P, Sriudomporn N, Setthaudom C, Maude RR, Osiri S. Immunogenicity and adverse effects of the third booster dose with ChAdOx1 among dental care workers after receiving a full dose of CoronaVac. M Dent J [Internet]. 2022 Jun. 18 [cited 2024 Jun. 16];42(2):77-88. Available from: https://he02.tci-thaijo.org/index.php/mdentjournal/article/view/257157
Section
Original articles

References

Department of Disease control of Thailand. 2021. Guidance for COVID-19 vaccine administration in Thailand's COVID-19 outbreak 2021. Department of Disease Control. Accessed 11 Feb 2022. Available from: https://ddc.moph.go.th/uploads/files/1729520210301021023.pdf.

Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398: 213-22.

Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med 2021; 385: 946-8.

Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med 2021; 385: 585-94.

Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. Lancet Infect Dis 2021; 21: 1352-4.

Munro AP, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021; 398: 2258-76.

Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 2021; 398: 981-90.

Zeng G, Wu Q, Pan H, Zeng G, Yang J, Jiang D, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. Lancet Infect Dis 2021; 22: 483-95.

Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med 2021; 27: 2136-43.

Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet 2021; 398: 207-9.

Fallahi HR, Keyhan SO, Zandian D, Kim S-G, Cheshmi B. Being a front-line dentist during the Covid-19 pandemic: a literature review. Maxillofac Plast Reconstr Surg 2020; 42: 1-9.

Singhal S, Warren C, Hobin E, Smith B. How Often Are Dental Care Workers Exposed to Occupational Characteristics that Put Them at Higher Risk of Exposure and Transmission of COVID-19? A Comparative Analysis. J Can Dent Assoc 2021; 87: l16.

Department of Disease Control of Thailand. 2021. Guidelines for clinical practice, diagnosis, treatment and prevention of healthcare-associated infection in response to patients with COVID-19 infection. Department of Disease Control. Accessed 11 Feb 2022. Available from: https://covid19.dms.go.th/backend/Content/Content_File/Covid_Health/Attach/25641103093725AM_update-CPG_COVID_v19.5_n_02211102.pdf.

Department of Disease Control of Thailand. 2021. Guidelines for Surveillance and Investigation of Coronavirus Disease 2019 (COVID-19). Department of Disease Control. Accessed 11 Feb 2022. Available from: https://ddc.moph.go.th/viralpneumonia/file/g_srrt/g_srrt_110864.pdf.

Department of Disease Control of Thailand. 2021. Guidance for COVID-19 vaccine administration in Thailand's COVID-19 outbreak 2021 (second edition). Department of Disease Control. Accessed 11 Feb 2022. Available from: https://ddc.moph.go.th/vaccine-covid19/getFiles/11/1628849610213.pdf.

Li X, Ghadami A, Drake JM, Rohani P, Epureanu BI. Mathematical model of the feedback between global supply chain disruption and COVID-19 dynamics. Sci Rep 2021; 11: 15450.

Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. eBioMedicine 2022; 75: 103761.

Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022; 399: 36-49.

Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis 2021; 21: 1212-3.

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021; 398: 121-30.

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021; 398: 856-69.

Department of Disease Control of Thailand. 2021.Department of Disease Control's guidance for frontline healthcare workers in preventing COVID-19 infection. Department of Disease Control. Accessed 11 Feb 2022. Available from: https://ddc.moph.go.th/brc/news.php?news=19925&deptcode=brc&news_views=1791.

Yu F, Lau L-T, Fok M, Lau JY-N, Zhang K. COVID-19 Delta variants—Current status and implications as of August 2021. Precis Clin Med 2021; 4: 287-92.

Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis 2022; 22: 56-63.

Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine 2021; 40: 524-30.

Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol 2020; 20: 529-36.

Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2021; 27: 270-8.

Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines 2022; 10: 86.

De Santis GC, Mendrone A, Langhi D, Jr., Covas DT, Fabron A, Jr., Cortez AJP, et al. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19. Hematol Transfus Cell Ther 2021; 43: 212-3.

Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, Schmit J-L, et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front Microbiol 2020; 11(584251).

Organization WH. Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca: background document to the WHO Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca. World Health Organization; 2021.

Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022; 602: 654-6.

Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022; 28: 486-9.

Jantarabenjakul W, Sodsai P, Chantasrisawad N, Jitsatja A, Ninwattana S, Thippamom N, et al. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines 2022; 10: 639.

Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. J Infec 2022.

Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun 2022; 13: 1614.